ArticleAdvanced healthcare materials2026
A Modular Liver-Microbial Microfluidic Platform to Evaluate Therapeutic and Adverse Effects of Microbial Metabolites.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Gut microbial metabolites, particularly short-chain fatty acids (SCFAs) like butyrate, play a significant role in modulating non-alcoholic fatty liver disease (NAFLD). While animal studies show that butyrate-producing microbes can improve liver function, full recovery is hindered by unintended side effects from commensal bacteria. These underlying biomolecular mechanisms remain elusive, due to the lack of in vitro coculture models capable of systematically examine both the therapeutic benefits of engineered microbial metabolites and their potential adverse impacts. To address this, we developed a modular microfluidic platform to study the effects of live microbial metabolites on hepatic steatosis and liver function. We created a microfluidic-based hepatic steatosis model integrated with a compartmentalized microbial module, facilitating the study of how metabolites produced by live microbes affected the liver model. We compared the effects of synthetic SCFA supplementation with those of coculturing with a control and butyrate-producing E. coli Nissle 1917 (EcN) strains on hepatic steatosis. Our findings showed that live microbial coculture did not phenocopy exogenous SCFA treatment. While both treatments reduced steatotic lipid accumulation, live microbes induced inflammatory and hepatic metabolic changes, suggesting contributions from additional microbial factors, emphasizing the need to thoroughly assess side effects in liver disease treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.